Veracyte, Inc.
NASDAQVCYT enters the week carrying its worst month in recent memory — down 31% to $40.68 — and the post-earnings reset is still rippling through analyst desks and options markets alike. The clearest signal of where sentiment shifted is the July 30 earnings release. The stock fell 16.9% the next day and extended that to a 17.2% loss over five sessions — a punishing reaction that reset…
VCYT short interest falls 24% in a week to 7.7% of float, driven by covering amid analyst upgrades and positive momentum.
Snapshot as of 20 Sept 2026
VCYT enters the week carrying its worst month in recent memory — down 31% to $40.68 — and the post-earnings reset is still rippling through analyst desks and options markets alike. The clearest signal of where…
Veracyte arrives at today's after-hours print having shed more than 21% in the past month, with the stock closing Monday at $44.85 — and the week's damage of nearly 20% coming on top of an additional 3% drop in the…
Veracyte enters the post-earnings stretch with short sellers sitting on a meaningful but stabilising position — a setup where the headline numbers are less interesting than the direction of travel. Short interest has…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for VCYT — free to start on ORTEX.
Sign up for free →Open VCYT on ORTEX